| Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. | |
| | |
MedLine Citation:
|
PMID: 20218749 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Colesevelam hydrochloride (colesevelam), a non-absorbed, synthetic, lipid-lowering polymer, is a bile acid sequestrant. Colesevelam binds with high affinity to bile acids within the gastrointestinal tract, thereby inhibiting the reabsorption of bile acids, resulting in decreases in serum low-density lipoprotein cholesterol (LDL-C) levels. Colesevelam is available as tablets and as powder for oral suspension. At dosages of 3.75 g once daily or 1.875 g twice daily, colesevelam is approved in the US for the treatment of pediatric patients aged 10-17 years with heterozygous familial hypercholesterolemia. Colesevelam may be administered as monotherapy or in combination with an HMG-CoA reductase inhibitor (statin). A 32-week trial was conducted and consisted of a stablilization period ( approximately 4 weeks), a randomized period (8 weeks), an open-label period (18 weeks), and a 2-week follow-up period. In the 8-week, randomized, double-blind, placebo-controlled period of the trial, colesevelam (tablets), as monotherapy or with a statin, was an effective treatment for pediatric patients with heterozygous familial hypercholesterolemia. At week 8, recipients of colesevelam 3.75 g/day had significant percentage reductions from baseline in mean LDL-C levels (primary endpoint) compared with placebo recipients. Significant beneficial treatment effects for colesevelam 3.75 g/day versus placebo were also reported for several other lipid/lipoprotein parameters at week 8 of the study. The reported treatment effects on lipid/lipoprotein parameters were maintained over a subsequent 18-week, open-label, noncomparative period, when all patients received colesevelam 3.75 g/day. Colesevelam 3.75 g/day was generally well tolerated for up to 26 weeks by pediatric patients with heterozygous familial hypercholesterolemia. |
| | |
Authors:
|
Caroline M Perry |
Related Documents
:
|
9043839 - Randomized placebo-controlled study of the effects of simvastatin on haemostatic variab... 11978169 - Development of a pharmacist-managed lipid clinic. 16076469 - Association of depressive symptoms with coagulation factors in young healthy individuals. 3901389 - The effect of the synthetic steroid org od14 on fibrinolysis and blood lipids in postme... 15781429 - Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients w... 12027869 - Homocysteine and the stage of atherosclerotic disease: a study in patients suffering fr... 17944739 - Clinical trial: a randomized-controlled crossover study of intrapyloric injection of bo... 17895179 - Screening for depression in stroke: relationship to rehabilitation efficiency. 18545189 - The feasibility and efficacy of elastic resistance training for improving the velocity ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Paediatric drugs Volume: 12 ISSN: 1179-2019 ISO Abbreviation: Paediatr Drugs Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-11 Completed Date: 2010-06-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883685 Medline TA: Paediatr Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 133-40 Citation Subset: IM |
Affiliation:
|
Adis, a Wolters Kluwer Business, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Allylamine
/
adverse effects,
analogs & derivatives*,
pharmacology,
therapeutic use Anticholesteremic Agents / adverse effects, pharmacology, therapeutic use* Bile Acids and Salts / metabolism Child Cholesterol, LDL / blood, drug effects Drug Therapy, Combination Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hyperlipoproteinemia Type II / drug therapy*, physiopathology Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Bile Acids and Salts; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 107-11-9/Allylamine; 182815-44-7/colesevelam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Darunavir: In Treatment-Experienced Pediatric Patients with HIV-1 Infection.
Next Document: Improving hearing health for farming families.